



Agenda 2026

Extraordinary General Meeting of Shareholders ("EGM")
of Corbion N.V. ("Corbion")



Date 2 December 2026 **Time** 11.00 am CET
Place UP Office Building, Piet Heinkade 55, 1019 GM Amsterdam

Agenda 2026

Agenda

1. Opening
2. Composition of the Supervisory Board
Appointment of Mr. Alexander (Xander) Wessels (*Voting Item*)
3. Miscellaneous
4. Closing

For explanatory notes on agenda item 2, please see the following page.

Record Date

4 November 2026

(See www.corbion.com for the registration procedure)

Registration of Votes

In order to be able to correctly register the votes being cast during the meeting shareholders who wish to exercise their voting rights at the meeting are requested to register at the registration desk before the start of the meeting. After the close of the registration desk at 11.00 am CET registration will no longer be possible.

Notes to Item 2**Appointment of Mr. Alexander (Xander) Wessels (Voting item)**

Xander Wessels, a Dutch national, brings extensive experience in the life sciences, specialty chemicals and food ingredients industries, with deep expertise in strategy, operational excellence, international business leadership and value creation. Throughout his career, he has held a number of senior leadership positions, including Chief Executive Officer of Caldic, Chief Executive Officer of Archroma, and President and Chief Executive Officer of DSM Pharmaceutical Products. Earlier in his career, he also held senior leadership roles within DSM and Campina. Currently, he serves as Chair of the Supervisory Board of NRG PALLAS and Chair of Enza Zaden and is a member of the Board of Directors of Archroma.

Details of the proposed candidate:

Name	A. (Xander) Wessels (Dutch nationality)
Age	62
Current positions	• Chair of the Supervisory Board of NRG PALLAS; • Chair of Enza Zaden; and • Member of the Board of Directors of Archroma.
Previous positions	• Chief Executive Officer of Caldic; • Chief Executive Officer of Archroma; and • President and Chief Executive Officer of DSM Pharmaceutical Products
Reasons for nomination	The Supervisory Board believes that Mr. Wessels' experience in leading international B2B companies, driving transformation and operational performance, and serving on supervisory boards will be highly valuable as Corbion continues to execute BRIGHT 2030, strengthen performance and create long-term value for stakeholders.